BioVaxys to Present New Data on its DPX Immune Educating Platform at Personalized Cancer Vaccine Summit

Rhea-AI Summary

BioVaxys Technology Corp. (BVAXF) has been invited to present at The Personalized Cancer Vaccine Summit in Boston, MA, from December 3-5, 2024. The presentation, titled "A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies," will showcase new data on the company's DPX Immune Educating Platform.

Chief Medical Officer David Berd, MD, will present findings from recent in vivo studies conducted by researchers at UConn Health and The Ohio State University Comprehensive Cancer Center. The data suggests that DPX has a significant role in delivering tumor neoepitope vaccines that induce tumor rejection and may possess anti-tumor capacity on its own.

BioVaxys is continuing additional studies on DPX's potential in delivering tumor neoepitope vaccines and its anti-tumor capabilities.

VANCOUVER, BC, Sept. 4, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") is pleased to announce that it has been invited to present "A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies" at The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) to be held December 3-5, 2024, in Boston, MA.

The 3-day program brings together top industry players developing individualized approaches in mRNA, DNA, peptide, viral, dendritic cells, and optimizing personalized cancer vaccine approaches with immune-checkpoint inhibitor combinations to combat multiple tumor specific pathways and minimize off-target effects. In addition to BioVaxys, other companies and organizations invited to present include BioNTec, CureVac, ImVax, The Mayo Clinic, and NEC Biotherapeutics.

BioVaxys Chief Medical Officer David Berd, MD, will present new data from recent in vivo studies of DPX conducted by Pramrod K. Srivastava, Ph.D., M.D., Professor, Department of Immunology, Director, Center for Immunotherapy of Cancer and Infectious Diseases and the Carole and Ray Neag Comprehensive Cancer Center at UConn Health, University of Connecticut, and Hakimeh Ebrahimi-Nik, DVM, Ph.D., Assistant Professor, Medical Oncology, The Ohio State University Comprehensive Cancer Center.

BioVaxys President and Chief Operating Officer Kenneth Kovan stated, "We will be withholding detailed disclosure on potential new therapeutic roles for DPX and neoepitopes until the conference, but suffice to say, the data suggests DPX has a significant role in the delivery of tumor neoepitope vaccines that induce tumor rejection, and DPX on its own appears to have an anti-tumor capacity."

BioVaxys is advancing additional studies with Dr. Nik and her research team on DPX delivering tumor neoepitope vaccines that induce tumor rejection, and DPX anti-tumor capacity.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© "neoantigen" tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© "neoantigen" tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed "James Passin"

James Passin, Chief Executive Officer

Phone: +1 646 452 7054
Email: jpassin@biovaxys.com

Cautionary Statements Regarding Forward Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved.. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Logo - https://mma.prnewswire.com/media/2415135/4890961/BioVaxys_Technology_Corp_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/biovaxys-to-present-new-data-on-its-dpx-immune-educating-platform-at-personalized-cancer-vaccine-summit-302237831.html

SOURCE BioVaxys Technology Corp.

FAQ

What event is BioVaxys (BVAXF) presenting at in December 2024?

BioVaxys (BVAXF) is presenting at The Personalized Cancer Vaccine Summit in Boston, MA, from December 3-5, 2024.

What is the focus of BioVaxys' (BVAXF) presentation at the summit?

BioVaxys (BVAXF) will present new data on its DPX Immune Educating Platform, focusing on a novel delivery system for personalized peptide and mRNA vaccines for more targeted therapies.

Who will be presenting the new data for BioVaxys (BVAXF) at the summit?

BioVaxys (BVAXF) Chief Medical Officer David Berd, MD, will present the new data at the summit.

What do the recent studies suggest about BioVaxys' (BVAXF) DPX platform?

Recent studies suggest that BioVaxys' (BVAXF) DPX platform has a significant role in delivering tumor neoepitope vaccines that induce tumor rejection and may have anti-tumor capacity on its own.

Is BioVaxys (BVAXF) conducting further research on the DPX platform?

Yes, BioVaxys (BVAXF) is advancing additional studies on DPX delivering tumor neoepitope vaccines and its anti-tumor capacity with researchers from The Ohio State University Comprehensive Cancer Center.